ALS sidelined this Israeli TV journalist. AI is helping him make a comeback.
A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using ...
ALS drugs from Denali, Calico come up short, marking setback for Healey trial
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
BioSpace1d
HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
Minnetonka woman helping connect ALS community through app "Pathfinders"
After her son was diagnosed with ALS, Faith thrust herself into research and organizations supporting the cure for ALS. She ...
ALS drug from Google-backed anti-aging company Calico fails clinical test
Age is an issue of mind over matter — h/t Mark Twain — but early ALS clinical trial results from Google-backed aging-disease ...
Becker's Hospital Review4d
Google's ALS drug fails phase 3 trial
A clinical trial evaluating the drug fosigotifator in patients with amyotrophic lateral sclerosis has failed to meet its primary endpoint, according to topline results from the Healey ALS platform ...
Crain's Chicago Business3d
AbbVie and rival's ALS drugs both disappoint in study
In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...
ALS News Today2d
DNL343, fosigotifator fail HEALEY platform trial’s main goal in ALS
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the ...